Stock info Santhera Pharmaceutical | Filter  Basic-Info

Santhera Pharmaceutical

The past year yielded positive returns for Santhera Pharmaceutical investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Santhera Pharmaceutical. The stock lost around 49 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 801 percent. Santhera Pharmaceutical's revenues between 2011 and 2015 were relatively stable and moved between 3,54 million CHFF and 4,32 million CHFF. The net results between 2011 and 2015 were far from constant and fluctuated between -27,84 million CHFF and -11,67 million CHFF.

The global pharmaceutical companies gained around 75 percent over the period 2006-2016. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

Over the past 5 years the Swiss company paid out dividends.

At the end of 2015 around 673 people were employed at Santhera Pharmaceutical.

Quite a lot of debt Santhera Pharmaceutical

At the end of 2015 the Swiss company's balance sheet was worth 117,15 million CHFF. 10,9 million CHFF (9,3 percent of the total balance sheet) was financed by debt. As per the end of 2015 Santhera Pharmaceutical's price/earnings-ratio equaled -39. So investors paid for 1 stock -39 times the earnings per share of 2015. Based on the classical stock valuation theories the Swiss stock can be seen as a growth stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 477,94 million CHFF. At the end of 2015 the Swiss company had around 5,34 million stocks listed.

All the annual reports of Santhera Pharmaceutical are available here. More information about Santhera Pharmaceutical can be found it's website. .